NASDAQ:ASND - Ascendis Pharma A/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $56.07 -4.93 (-8.08 %) (As of 11/15/2018 06:00 AM ET)Previous Close$61.00Today's Range$53.2050 - $61.3052-Week Range$33.94 - $76.99Volume246,500 shsAverage Volume144,549 shsMarket Capitalization$2.53 billionP/E Ratio-12.95Dividend YieldN/ABeta0.82 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark. Receive ASND News and Ratings via Email Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASND Previous Symbol CUSIPN/A Webwww.ascendispharma.com Phone45-7022-2244 Debt Debt-to-Equity RatioN/A Current Ratio9.87 Quick Ratio9.87 Price-To-Earnings Trailing P/E Ratio-12.95 Forward P/E Ratio-13.29 P/E GrowthN/A Sales & Book Value Annual Sales$1.80 million Price / Sales1,309.23 Cash FlowN/A Price / CashN/A Book Value$5.82 per share Price / Book9.63 Profitability EPS (Most Recent Fiscal Year)($4.33) Net Income$-140,040,000.00 Net Margins-17,641.85% Return on Equity-49.69% Return on Assets-45.56% Miscellaneous Employees137 Outstanding Shares42,030,000Market Cap$2.53 billion OptionableOptionable Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions What is Ascendis Pharma A/S's stock symbol? Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND." How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings data on Wednesday, August, 29th. The biotechnology company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.37. The biotechnology company earned $0.02 million during the quarter, compared to the consensus estimate of $0.16 million. Ascendis Pharma A/S had a negative net margin of 17,641.85% and a negative return on equity of 49.69%. View Ascendis Pharma A/S's Earnings History. When is Ascendis Pharma A/S's next earnings date? Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Thursday, November 15th 2018. View Earnings Estimates for Ascendis Pharma A/S. What price target have analysts set for ASND? 9 brokers have issued 12 month price objectives for Ascendis Pharma A/S's stock. Their forecasts range from $60.00 to $88.00. On average, they anticipate Ascendis Pharma A/S's stock price to reach $77.50 in the next year. This suggests a possible upside of 38.2% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S. What is the consensus analysts' recommendation for Ascendis Pharma A/S? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S. Has Ascendis Pharma A/S been receiving favorable news coverage? News articles about ASND stock have trended somewhat positive on Thursday, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a news impact score of 1.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days. Who are some of Ascendis Pharma A/S's key competitors? Some companies that are related to Ascendis Pharma A/S include Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Nektar Therapeutics (NKTR), Amneal Pharmaceuticals (AMRX), Beigene (BGNE), Amarin (AMRN), SAGE Therapeutics (SAGE), Dr.Reddy's Laboratories (RDY), Catalent (CTLT) and Alkermes (ALKS). Who are Ascendis Pharma A/S's key executives? Ascendis Pharma A/S's management team includes the folowing people: Michael Wolff Jensen, Chairman, SVP & General CounselJan Møller Mikkelsen, President, Chief Executive Officer & DirectorNeil T. Ringdahl, Chief Operating OfficerScott T. Smith, Chief Financial Officer & Senior Vice PresidentHarald Rau, Chief Scientific Officer & Senior Vice President When did Ascendis Pharma A/S IPO? (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (9.88%), Alliancebernstein L.P. (1.70%), Franklin Resources Inc. (1.41%), BlackRock Inc. (1.10%), First Manhattan Co. (0.65%) and Foresite Capital Management IV LLC (0.58%). Which institutional investors are selling Ascendis Pharma A/S stock? ASND stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, First Manhattan Co., Allianz Asset Management GmbH, Foresite Capital Management IV LLC, Renaissance Technologies LLC, Matisse Capital, University of Notre Dame DU Lac and Victory Capital Management Inc.. Which institutional investors are buying Ascendis Pharma A/S stock? ASND stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Loomis Sayles & Co. L P, FIL Ltd, Fosun International Ltd, Franklin Resources Inc., DekaBank Deutsche Girozentrale, BlackRock Inc. and Tekla Capital Management LLC. How do I buy shares of Ascendis Pharma A/S? Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ascendis Pharma A/S's stock price today? One share of ASND stock can currently be purchased for approximately $56.07. How big of a company is Ascendis Pharma A/S? Ascendis Pharma A/S has a market capitalization of $2.53 billion and generates $1.80 million in revenue each year. The biotechnology company earns $-140,040,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. Ascendis Pharma A/S employs 137 workers across the globe. What is Ascendis Pharma A/S's official website? The official website for Ascendis Pharma A/S is http://www.ascendispharma.com. How can I contact Ascendis Pharma A/S? Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected] MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 187 (Vote Outperform)Underperform Votes: 185 (Vote Underperform)Total Votes: 372MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: What are defining characteristics of a correction?